| Literature DB >> 27320287 |
Olga Pivovarova1,2,3, Annika Höhn3,4, Tilman Grune3,4,5, Andreas F H Pfeiffer1,2,3, Natalia Rudovich1,2,3.
Abstract
Insulin-degrading enzyme (IDE) is a major enzyme responsible for insulin degradation. In addition to insulin, IDE degrades many targets including glucagon, atrial natriuretic peptide, and beta-amyloid peptide, regulates proteasomal degradation and other cell functions. IDE represents a pathophysiological link between type 2 diabetes (T2DM) and late onset Alzheimer's disease (AD). Potent and selective modulators of IDE activity are potential drugs for therapies of both diseases. Acute treatment with a novel IDE inhibitor was recently tested in a mouse study as a therapeutic approach for the treatment of T2DM. In contrast, effective IDE activators can be used for the AD treatment. However, because of the pleiotropic IDE action, the sustained treatment with systemic IDE modulators should be carefully tested in animal studies. Development of substrate-selective IDE modulators could overcome possible adverse effects of IDE modulators associated with multiplicity of IDE targets. KEY MESSAGES Insulin-degrading enzyme (IDE) represents a pathophysiological link between type 2 diabetes (T2DM) and Alzheimer's disease (AD). Selective modulators of IDE activity are potential drugs for both T2DM and AD treatment. Development of substrate-selective IDE modulators could overcome possible adverse effects of IDE modulators associated with multiplicity of IDE targets.Entities:
Keywords: Alzheimer’s disease; insulin-degrading enzyme; type 2 diabetes
Mesh：
Substances：
Year: 2016 PMID： 27320287 DOI： 10.1080/07853890.2016.1197416
Source DB: PubMed Journal: Ann Med ISSN： 0785-3890 Impact factor: 4.709